Related Experiment Videos
Magnetic resonance spectroscopy in affective disorders
1Department of Psychiatry, Shiga University of Medical Science, Japan. tadafumi-tky@umin.ac.jp
Summary
Magnetic resonance spectroscopy (MRS) reveals brain chemistry changes in affective disorders. Lithium treatment impacts brain phosphomonoester levels, while MRS also tracks drug pharmacokinetics.
Area of Science:
- Neuroimaging
- Biochemistry
- Psychopharmacology
Background:
- Affective disorders are associated with neurobiological and psychopharmacological alterations.
- Magnetic resonance spectroscopy (MRS) offers non-invasive in vivo chemical analysis for studying these conditions.
Purpose of the Study:
- To investigate brain chemical changes in affective disorders using MRS.
- To explore the effects of treatments like lithium and fluoxetine on brain metabolism and drug pharmacokinetics.
Main Methods:
- Utilized phosphorus-31 (31P-MRS) and proton (1H-MRS) to assess phospholipid and high-energy phosphate metabolism, and intracellular pH.
- Employed lithium-7 (7Li-MRS) and fluorine-19 (19F-MRS) to determine the brain pharmacokinetic properties of lithium, fluoxetine, and fluvoxamine.
Main Results:
- 31P-MRS and 1H-MRS indicated potential abnormalities in membrane phospholipid metabolism, high-energy phosphate metabolism, and intracellular pH in affective disorders.
- Lithium treatment appeared to increase brain phosphomonoester (potentially inositol-1-phosphate) but not choline-containing compounds.
- 7Li-MRS and 19F-MRS successfully elucidated the brain pharmacokinetic profiles of lithium, fluoxetine, and fluvoxamine.
Conclusions:
- MRS is a valuable tool for understanding the neurobiological underpinnings of affective disorders.
- MRS can monitor treatment effects, such as lithium's impact on brain metabolites, and drug distribution in the brain.